

WHAT IS CLAIMED IS:

Claim 1. Use of an anti-PD-L1 antibody or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of a tumor in a subject in need thereof,

wherein the anti-PD-L1 antibody or an antigen-binding fragment thereof is to be administered at 20 mg/kg in combination with an anti-CTLA-4 antibody or an antigen-binding fragment thereof on day 1 of treatment, followed by administration of 20 mg/kg of the anti-PD-L1 antibody or antigen-binding fragment thereof every 4 weeks, and

wherein the anti-CTLA-4 antibody or an antigen-binding fragment thereof is to be administered at 4 mg/kg as a single dose on day 1 of treatment.

Claim 2. The use according to claim 1, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is tremelimumab.

Claim 3. The use according to claim 1 or 2, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is durvalumab.

Claim 4. The use to any one of claims 1 to 3, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof and the anti-CTLA-4 antibody or antigen-binding fragment thereof are to be administered to the subject simultaneously, separately, or sequentially.

Claim 5. The use according to any one of claims 1 to 4, wherein the medicament is to be administered in combination with transarterial chemoembolization (TACE) to the subject.

Claim 6. The use according to any one of claims 1 to 5, wherein the tumor is a hepatocellular carcinoma (HCC).

Claim 7. Use of an anti-PD-L1 antibody or an antigen-binding fragment thereof in the manufacture of a medicament for the treatment of a tumor in a subject in need thereof,
wherein the anti-PD-L1 antibody or an antigen-binding fragment thereof is to be administered at 1500 mg in combination with an anti-CTLA-4 antibody or an antigen-binding fragment thereof on day 1 of treatment, followed by administration of 1500 mg of the anti-PD-L1 antibody or antigen-binding fragment thereof every 4 weeks, and

wherein the anti-CTLA-4 antibody or an antigen-binding fragment thereof is to be administered at 300 mg as a single dose on day 1 of treatment.

Claim 8. The use according to claim 7, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is tremelimumab.

Claim 9. The use according to claim 7 or 8, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is durvalumab.

Claim 10. The use according to any one of claims 7 to 9, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof and the anti-CTLA-4 antibody or antigen-binding fragment thereof are to be administered to the subject simultaneously, separately, or sequentially.

Claim 11. The use according to any one of claims 7 to 10, wherein the medicament is to be administered in combination with transarterial chemoembolization (TACE) to the subject.

Claim 12. The use according to any one of claims 7 to 11, wherein the tumor is a hepatocellular carcinoma (HCC).